GSA Capital Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-108,229	Closed	-$844K	–	1723
2025 Q4	$844K	Sell	108,229 -82,065	-43%	-$593K	0.07%	459
2025 Q3	$1.44M	Buy	190,294 +78,827	+71%	+$656K	0.12%	194
2025 Q2	$999K	Sell	111,467 -167,085	-60%	-$1.56M	0.07%	450
2025 Q1	$2.09M	Buy	278,552 +114,068	+69%	+$920K	0.19%	58
2024 Q4	$1.24M	Sell	164,484 -121,104	-42%	-$919K	0.09%	273
2024 Q3	$2.17M	Sell	285,588 -78,250	-22%	-$595K	0.16%	101
2024 Q2	$2.25M	Buy	+363,838	New	+$2.01M	0.16%	109
2024 Q1	–	Sell	-178,769	Closed	-$1.07M	–	1609
2023 Q4	$1.07M	Sell	178,769 -12,758	-7%	-$73.9K	0.09%	355
2023 Q3	$1.36M	Buy	191,527 +119,995	+168%	+$862K	0.12%	260
2023 Q2	$504K	Sell	71,532 -82,186	-53%	-$660K	0.05%	723
2023 Q1	$1.28M	Buy	+153,718	New	+$1.48M	0.13%	196
2022 Q4	–	Sell	-19,121	Closed	-$241K	–	1468
2022 Q3	$241K	Buy	+19,121	New	+$246K	0.03%	1075
2021 Q4	–	Sell	-41,116	Closed	-$591K	–	1411
2021 Q3	$591K	Buy	+41,116	New	+$648K	0.06%	597
2021 Q2	–	Sell	-80,197	Closed	-$816K	–	1320
2021 Q1	$816K	Buy	80,197 +69,697	+664%	+$719K	0.14%	174
2020 Q4	$78K	Buy	+10,500	New	+$54.1K	0.01%	1118
2020 Q3	–	Sell	-39,599	Closed	-$189K	–	1243
2020 Q2	$189K	Sell	39,599 -99,065	-71%	-$396K	0.11%	367
2020 Q1	$277K	Buy	+138,664	New	+$382K	0.07%	536
2019 Q2	–	Sell	-40,383	Closed	-$329K	–	1440
2019 Q1	$329K	Buy	+40,383	New	+$346K	0.03%	942
2017 Q4	–	Sell	-13,086	Closed	-$69K	–	1554
2017 Q3	$69K	Buy	+13,086	New	+$67K	﹤0.01%	1541
2015 Q1	–	Sell	-35,350	Closed	-$430K	–	2094
2014 Q4	$430K	Sell	35,350 -19,324	-35%	-$213K	0.03%	1030
2014 Q3	$535K	Buy	+54,674	New	+$670K	0.03%	895